Beta Bionics, Inc.
NASDAQ:BBNXMedical - Equipment & Services
+$0.42 today
- Market cap
- $644.70M
- Beta
- 3.39
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.50
Volume 1.38M
Average 0.99M
BBNX Deferred Revenue (Non-current)
Payments received for goods or services the company will deliver after more than one year.
Beta Bionics, Inc.NASDAQ: BBNX
Deferred Revenue (Non-current) · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue (non-current) rises 43.8% from a year ago
Deferred revenue (non-current) stood at $3.35M at the end of Q1 FY2026, up 43.8% from a year earlier and up 1.6% from the prior quarter.
Context
- Deferred revenue (non-current) amounted to 1.1% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Deferred revenue (non-current) increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether deferred revenue (non-current) keeps rising in the next quarterly balance sheet after a +43.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue (Non-current) history
USD · from the balance sheet
- Latest · FY2025
- 3.3M USD
- Year-over-year change
- +77.3%
| Period | Period end | Deferred Revenue (Non-current) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.3M | +77.3% |
| FY2024 | 2024-12-31 | 1.86M | +629.4% |
| FY2023 | 2023-12-31 | 255K | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue (Non-current) vs competitors
How BBNX compares with its peers on the latest reported figures
- Peers report in different currencies, so deferred revenue (non-current) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +43.8% is the 2nd highest of 6, against a peer median of -18.9%.
- Deferred revenue (non-current) amounts to 1.1% of total assets for BBNX, versus a peer median of 0.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $38.91M USD | -17.9% | +2.0% | 5.2% | |
| Mar 2026 | $7.99M USD | -18.9% | -20.5% | 0.7% | |
MMEDMiniMed Group, Inc. Common Stock | Jul 2026 | $5M USD | — | — | 0.1% |
| Mar 2026 | $3.35M USD | +43.8% | — | 1.1% | |
| Jun 2026 | $2.1M USD | +50.0% | -2.1% | 0.1% | |
| Mar 2026 | $1.53M USD | -23.5% | -6.5% | 0.6% | |
| Jun 2026 | DKK 0 DKK | — | — | 0.0% | |
| Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding BBNX) | — | -18.9% | -4.3% | 0.1% | |
Competitors are the stored peer set for BBNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Beta Bionics, Inc.
NASDAQ:BBNX
Intrinsic Alpha fair value
Locked
Current Price
$14.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.